Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZA-PLUS: Azacitidine Combinations in High-Risk MDS
NCT01342692Phase 2Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2011
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of valproic acid, lenalidomide and idarubicin in myelodysplastic syndrome (MDS) (4 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Remission (complete, partial or medullary) after 6 cycles at 6 months. Status: unknown.
02
Drugs
valproic acidlenalidomideidarubicin
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01342692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01342692.